Core Insights - Immix Biopharma has initiated the U.S. NEXICART-2 trial for NXC-201, a CAR-T cell therapy targeting AL Amyloidosis, with the first patient dosed at Memorial Sloan Kettering Cancer Center [1][3] - The NEXICART-2 study aims to evaluate the safety and efficacy of NXC-201 in relapsed/refractory AL Amyloidosis patients, building on positive results from the NEXICART-1 trial which reported a 92% overall response rate [2][4] - NXC-201 is the only CAR-T therapy currently in development for AL Amyloidosis, with the potential to become a first-in-class treatment [3][7] Company Overview - Immix Biopharma is a clinical-stage biopharmaceutical company focused on cell therapies for AL Amyloidosis and autoimmune diseases, with NXC-201 as its lead candidate [9] - The company has received Orphan Drug Designation for NXC-201 in both the U.S. and EU [7][9] Clinical Trials - NEXICART-2 is a Phase 1b/2 trial designed to enroll 40 patients with adequate cardiac function who have not received prior BCMA-targeted therapy, evaluating two doses of NXC-201 [4] - The primary endpoints of the trial include complete response rate and overall response rate, following consensus recommendations [4] Market Context - The prevalence of relapsed/refractory AL Amyloidosis in the U.S. is estimated to grow at 12% per year, reaching approximately 33,277 patients in 2024 [8] - The amyloidosis market was valued at $3.6 billion in 2017 and is projected to reach $6 billion by 2025 [8]

Core Insights - Senti Biosciences, Inc. has received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to support the clinical development of its investigational cell therapy SENTI-202 for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML) [1][2] - The ongoing Phase 1 clinical trial of SENTI-202 is evaluating two dose levels (1 billion or 1.5 billion cells) and aims to provide initial efficacy data by the end of 2024 and durability data in 2025 [1][2] Company Overview - Senti Bio is focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, which aims to enhance precision and control in targeting cancer cells while sparing healthy cells [6] - The company is leveraging off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells outfitted with Gene Circuits to address challenging liquid and solid tumor indications [6] Product Details - SENTI-202 is designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, such as AML and myelodysplastic syndrome (MDS), while protecting healthy bone marrow cells [3] - The therapy incorporates an OR GATE for activating CAR targeting CD33 and FLT3, a NOT GATE to protect healthy cells, and calibrated-release IL-15 technology to enhance cell persistence and activity [3] Clinical Trial Information - The Phase 1 trial (NCT06325748) is currently enrolling adult patients with relapsed or refractory CD33 and/or FLT3 expressing hematologic malignancies at multiple sites in the U.S. and Australia [2][3] - Patients may receive multiple treatment cycles based on safety and efficacy data, with each cycle consisting of three doses administered weekly [2] Market Context - Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults, with an estimated 20,800 new cases in the U.S. in 2024 and a five-year survival rate of approximately 30% [5] - Current treatment options for relapsed or refractory AML are limited, with a median overall survival of less than seven months [5]

Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinomaNomination triggers a $2 million milestone payment to CarismaPHILADELPHIA, June 27, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of the first development candidate ("Development Candidate"), under its collaboration ...

Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date (150 x 106 CAR T cells)First demonstration that CAR T cells enhanced with anti-exhaustion technology can both expand and infiltrate into solid tumorsNo significant safety signal related to LYL797 observed in patients without lung involvement; treatable pneumonitis observed in patients with lung metastatic disease; ...

This patient is expected to be the final patient in the second dosage cohort of the trialSAN JOSE, Calif., June 24, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has treated the sixth patient in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. This patient is expected to be the last patient in the seco ...

This IND clearance expands the use of KYV-101 CAR T-cell therapy in a Phase 2, open-label KYSA-8 clinical trial targeting a devastating neuroimmunological autoimmune diseaseKYV-101 is a fully human anti-CD19 CAR T-cell therapy designed for use in patients with B cell-driven autoimmune diseasesEMERYVILLE, Calif., June 20, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from auto ...

ALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure RatesFirst Prospective Trial to Incorporate the Foresight Diagnostics’s Investigational CLARITY™ Test to Identify Patients with LBCL Who Have Minimal Residual Disease (MRD) and are Likely to Relapse Following Standard 1L TreatmentUnique Profile of Investigational AlloCAR T™ Products May Expand Access to CAR T within Community Cancer Centers where Most 1L Patients are ManagedALPHA3 Expected to Co ...

PONTE VEDRA BEACH, Fla. and PARSIPPANY, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- AVIS, one of the world's best known car rental brands, has today announced a multi-year extension of its partnership as the Official Rental Car Company of the PGA TOUR, PGA TOUR Champions and Korn Ferry Tour. The agreement, through 2028, will continue to provide rental vehicles for players, caddies, employees and fans at PGA TOUR-sanctioned events worldwide. AVIS has been an Official Marketing Partner and the preferred rental ca ...

Core Insights - Avis Budget Group is focusing on digital transformation strategies and innovation programs to enhance its technology operations and improve customer service [1][3]. Group 1: Technology Initiatives - The report provides an overview of Avis' technology initiatives, including partnerships, product launches, and investments aimed at enhancing operational efficiency and profitability [2][3]. - Avis has developed a cloud-based data and analytics architecture utilizing solutions from Informatica and AWS for real-time analytics on connected car data [4]. - The company is leveraging emerging technologies such as AI, machine learning, big data, cloud computing, IoT, and e-commerce to drive its digital transformation [4]. Group 2: Business Segments - Avis operates under two reportable business segments: the Americas and international, with the Americas segment focusing on vehicle rental and car sharing in North America, Central America, South America, and the Caribbean [2]. - The international segment includes vehicle rental operations in regions such as Australasia, Asia, Africa, the Middle East, and Europe, along with car sharing and licensing operations [2]. Group 3: ICT Budgets and Contracts - The report includes details on Avis' estimated ICT budgets and major ICT contracts, providing insights into the company's technological investments and priorities [2][3]. Group 4: Key Topics Covered - Key topics in the report include digital transformation strategy, technology initiatives, investments, and a network map of partnerships, investments, and acquisitions [6].

Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months All patients were heavily pretreated/refractory to BTK inhibitors, and only one patient has started new anti-WM treatment after MB-106 Outpatient administration was allowed and found to be feasible Currently no FDA-approved CAR-T treatments for WM Data presented at the European Hematology Association 2024 Hybrid Congress WORCESTER, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Mustang Bi ...